A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266.
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2015
At a glance
- Drugs MK 8266 (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 13 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2010 Actual initiation date (Nov 2010) added as reported by ClinicalTrials.gov.
- 19 Nov 2010 Planned End Date changed from Sep 2010 to Nov 2010 as reported by ClinicalTrials.gov.